SciSparc (NASDAQ:SPRC – Get Free Report) and ProPhase Labs (NASDAQ:PRPH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.
Earnings and Valuation
This table compares SciSparc and ProPhase Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SciSparc | $860,000.00 | 4.02 | -$12.18 million | N/A | N/A |
| ProPhase Labs | $5.06 million | 0.15 | -$53.36 million | ($3.90) | -0.03 |
Volatility and Risk
SciSparc has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for SciSparc and ProPhase Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SciSparc | 1 | 0 | 0 | 0 | 1.00 |
| ProPhase Labs | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares SciSparc and ProPhase Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SciSparc | N/A | N/A | N/A |
| ProPhase Labs | -825.01% | -482.05% | -88.90% |
Institutional and Insider Ownership
25.1% of SciSparc shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
SciSparc beats ProPhase Labs on 7 of the 9 factors compared between the two stocks.
About SciSparc
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
